Study at University Medicine Halle points to success of immunotherapy in the treatment of advanced stomach cancer

A clinical trial conducted by researchers at University Medicine Halle has shown that the lives of patients with a certain form of stomach cancer can be significantly prolonged when the current standard of care, which uses a combination of antibody therapy and chemotherapy to inhibit cell growth through receptor blockades, is supplemented by immunotherapy with the drug nivolumab.

Quelle: IDW Informationsdienst Wissenschaft